InvestorsHub Logo
Followers 26
Posts 4067
Boards Moderated 0
Alias Born 12/26/2018

Re: seek the light post# 275025

Tuesday, 10/22/2019 7:09:15 PM

Tuesday, October 22, 2019 7:09:15 PM

Post# of 403047
You're underestimating Galera's GC4419. Their phase 2 data was far more compelling than ours and the FDA agrees (they got BTD, we did not). We would be in serious trouble if B-OM was not a mouth rinse rather than an IV.

Prior to the Galera results, B-OM was going to waltz into a bluesky opportunity with superior efficacy and delivery method as compared to everything including the Soligenix drug. GC4419 will succeed in phase 3 and will put a significantly higher floor under the standard of care for OM. Galera has added considerable risk to anyone looking to buy/partner B-OM because of this. I wouldn't be surprised if this is part of the reason why we have not partnered it yet - I would guess the offers are lower than we would like with competition and no BTD.

If we had double the number of patients in our B-OM phase 2 or had cleaner results this situation would be looking more in our favor. For now it's a coin toss though. Fortunately we have the superior delivery method.

Go IPIX!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News